Post-earnings recap
Reported
Thu, May 8, 2025
EPS actual
$-0.24
EPS est.
$-0.18
EPS surprise
-33.33%
1-day move
+2.20%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a loss that was wider than expected, which typically raises concerns among investors. However, the stock rose by 2.20%, likely due to market optimism or other factors unrelated to the earnings report. The lack of revenue data and guidance may leave investors cautious moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.24 | N/A | -33.33% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over recent performance but remains focused on future opportunities. They did not provide specific guidance for upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategic goals despite current setbacks.